Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,012 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adverse Events Clear all
Completed No phase listed Observational

Cardiovascular Effects of CART Cell Therapy

NCT04026737
View directory record Official record
Conditions
Leukemia, Lymphoma, Cardiotoxicity, Risk Factor, Cardiovascular, Immunotherapy
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Withdrawn Not applicable Interventional

Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO

NCT03673566
View directory record Official record
Conditions
Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less), Neonatal Infection, Satisfaction, Stress, Chronic Lung Disease, Growth Acceleration, Adverse Event
Interventions
NICU Dashboard
Device
Lead sponsor
Philips Healthcare
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences

NCT05407129
View directory record Official record
Conditions
Family Reported Errors and Adverse Events, Health Disparities, Family Safety Reporting, Patient Safety, Voluntary Incident Reporting, Quality Improvement
Interventions
Family safety reporting intervention
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
656 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Completed No phase listed Observational Results available

Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event

NCT00785044
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
I-123 mIBG
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting Phase 2 Interventional

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

NCT06470971
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions
Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Siltuximab
Biological · Procedure · Other
Lead sponsor
Yuanquan Yang
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting Phase 1 Interventional

IL-17 Blockade to Decrease irAEs (REPLAY)

NCT07237594
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Secukinumab Injection
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Results available

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

NCT03461445
View directory record Official record
Conditions
Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity
Interventions
Envarsus, IR Tacrolimus
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
60 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 30, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional

Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy

NCT03108911
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Best Practice, Biospecimen Collection, Dietary Intervention, Laboratory Biomarker Analysis
Other · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting No phase listed Observational

IPGx PILOT Whole Genome Sequencing Extension Cohort

NCT06766071
View directory record Official record
Conditions
Adverse Drug Reaction (ADR), Polypharmacy Patients
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bryan, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bringing I-PASS to the Bedside: A Communication Bundle to Improve Patient Safety and Experience

NCT02320175
View directory record Official record
Conditions
Communication
Interventions
Patient and Family Centered I-PASS
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
6,478 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
6
States / cities
Palo Alto, California • San Francisco, California • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

NCT00198419
View directory record Official record
Conditions
Drug Hypersensitivity
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

NCT05755035
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
TAK-881, HYQVIA
Biological
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Irvine, California • Walnut Creek, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Evaluation of an Interactive Opioid Risk Education Program (STOMP) for Parents

NCT03287622
View directory record Official record
Conditions
Pain, Postoperative, Medication Adherence, Opioid Use, Knowledge, Attitudes, Practice, Risk Reduction Behavior
Interventions
Educational Intervention, Nudge
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 99 Years
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Individualized Piano Instruction (IPI) for Improving Cognition in Breast Cancer Survivors.

NCT05909813
View directory record Official record
Conditions
Breast Cancer, Chemotherapy-Related Cognitive Impairment
Interventions
Individualized Piano Keyboard Instruction
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06568939
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, c-MET
Interventions
Telisotuzumab Vedotin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Chandler, Arizona • Little Rock, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

NCT01205503
View directory record Official record
Conditions
Breast Cancer, Non-Hodgkin's Lymphoma
Interventions
Mesna, Saline, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 30, 2026, 1:43 PM EDT
Active, not recruiting No phase listed Observational

Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients

NCT02390297
View directory record Official record
Conditions
HIV-1 Infection, Receipt of Cal-1 Modified Hematopoietic Cellular Products
Interventions
Blood tests
Genetic
Lead sponsor
Calimmune, Inc.
Industry
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Results available

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

NCT00980018
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
19
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 30, 2026, 1:43 PM EDT
Recruiting Not applicable Interventional

Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer

NCT05874297
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Best Practice, Internet-Based Intervention, Questionnaire Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 1:43 PM EDT
Terminated Phase 4 Interventional Results available

Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

NCT01250496
View directory record Official record
Conditions
Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

NCT00055718
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions
silymarin
Dietary Supplement
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
2 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
7
States / cities
Miami, Florida • Mineola, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 30, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

NCT04888585
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-154, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
101
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 30, 2026, 1:43 PM EDT
Not listed No phase listed Observational

DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

NCT00752960
View directory record Official record
Conditions
Psychoses
Interventions
Not listed
Lead sponsor
Genomas, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Hartford, Connecticut • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Oct 30, 2026, 1:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered

NCT02969343
View directory record Official record
Conditions
Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism, Patient Fall, Catheter-Associated Infection, Severe Hypoglycemia, Opioid-Related Severe Adverse Drug Event, Hospital Acquired Pressure Ulcer, Adverse Drug Event, Severe Hospital Acquired Delerium, Rapid Response Related to Arrhythmia
Interventions
Patient Safety health information technology
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
21,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 30, 2026, 1:43 PM EDT